Показаны сообщения с ярлыком treatment of ed. Показать все сообщения
Показаны сообщения с ярлыком treatment of ed. Показать все сообщения

среда, 22 декабря 2010 г.

Review shows dangers of erectile dysfunction drugs sold on the internet

A review from scientist in the UK, US and Sweden reveals that 90 percent of drugs for erectile dysfunction are now sold on the internet. Purchasing drugs to treat ED and other diseases from the internet can harm health by bypassing needed health. Many of the drugs also contain harmful ingredients.
The dangers of counterfeit drugs sold on the internet can also pose health risks from the impurity of the products. According to a review of studies, 2.3 million drugs for erectile dysfunction are sold monthly on the internet and mostly without prescription. Additionally, 44 per cent of the Viagra offered on the internet is counterfeit.
The focus of the analysis was on drugs sold on the internet to treat erectile dysfunction from 1995 to 2009, and included more than 50 studies.
Graham Jackson, a London-based cardiologist who led the study says, "We discovered that 150 patients had been admitted to hospitals in Singapore after taking counterfeit tadalfil [Cialis] and herbal preparations that claimed to cure ED. Seven were comatose, as the drugs contained a powerful drug used to treat diabetes, and four subsequently died."
Jackson warns that erectile dysfunction drugs are not the only counterfeit medications sold on the internet. "In Argentina, two pregnant women died after being given injections of a counterfeit iron preparation for anaemia and 51 children died in Bangladesh of kidney failure after taking paracetamol [acetaminophen] syrup contaminated with diethylene glycol, which is widely used as car antifreeze.”
Fake drugs sold on the internet included contraceptive and antimalaria pills, counterfeit antibiotics and water sold as a vaccine for meningitis. According to rough estimates, there could be as many as 2.5 million men in the Europe using counterfeit Viagra obtained from the internet without physician prescription or medical exam because of the embarrassment associated with erectile dysfunction. Analysis of ED drugs shows that some contain active ingredients while others contain contaminants that could harm health.
An analysis of Viagra seized by law enforcement agents revealed that a Hungarian sample contained amphetamine. In the UK, the “little blue pill” Viagra was colored with printer ink and contained caffeine and bulk lactose. Out of 370 alleged Viagra samples sold on the internet, seized by authorities, and then analyzed by the Dutch National Institute for Public Health, only 10 were genuine - the rest contained a variety of other drugs.
Fake drugs sold on the internet are profitable, and laws that apply in one country may not apply in another, making control of sales difficult. The World Health Organization views internet sales of drugs as a community health hazard that needs to be stopped. Jackson explains that “obstacles to effective action include the lack of a clear worldwide consensus on what constitutes a counterfeit drug and the fact that activities that are illegal in one country may be legal in another."
The study authors say clinicians should warn the public of the potential harm that can ensue from buying counterfeit drugs on the internet. In some cases selling fake drugs on the internet for erectile dysfunction and other health condition can be ten times as profitable per kilogram as heroin for unscrupulous marketers. The sale of counterfeit drugs can also lead people to avoid need health care, leaving conditions such as hypertension and diabetes undiagnosed.

среда, 15 декабря 2010 г.

King Pharmaceuticals Delays Program With Bremelanotide For Erectile Dysfunction

Palatin Technologies and King Pharmaceuticals have delayed plans for the initiation of Phase 3 clinical trials with bremelanotide, a first in class melanocortin agonist drug candidate, for the treatment of male erectile dysfunction (ED).
The decision follows responses from representatives of the U.S. Food and Drug Administration (FDA), which raised serious concerns about the acceptable benefit/risk ratio to support the progression of the proposed program into Phase 3 studies for ED.
After reviewing the data generated in the Phase 1 and 2 studies, the FDA questioned the overall efficacy results and the clinical benefit of this product in both the general and diabetic ED populations, and cited blood pressure increases as its greatest safety concern. Though not supportive of the proposed Phase 3 studies for ED with bremelanotide, the FDA stated that it was amenable to proposals for a different drug development pathway, such as for a second-line therapy in non-responders to currently approved PDE-5 inhibitors.
"The safety of patients in our clinical program has always been our number one priority and we will work closely with the FDA, King, and our advisors to determine the next steps for the program," stated Carl Spana, Ph.D., President and Chief Executive Officer of Palatin.
Palatin and King plan to review the FDA comments in the overall context of the program in order to determine next steps related to the further development of bremelanotide for the treatment of ED.
ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia, and smoking. In addition, certain prescription drugs and psychogenic issues may contribute to ED. It is estimated that some degree of ED affects one half of all men over the age of 40 and that 150 million men worldwide suffer from ED.